Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Krazati Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy N/A

    Krazati (adagrasib) Coverage Criteria

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for Krazati (adagrasib) for Colorado Rocky Mountain Health Plans members. Members younger than 19 years process automatically without coverage review; covered indications for older members require the diagnosis, KRAS G12C mutation, disease status, prior therapy, and continuation criteria specified below.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyKrazati (adagrasib) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for members 19 years and older using the applicable disease-specific or NCCN-recommended regimen criteria.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The August 2026 annual review added criteria for NCCN-recommended Krazati use in CNS cancer, appendiceal neoplasms and cancers, and small bowel adenocarcinoma.

    The August 2024 revision added NCCN-recommended Krazati criteria for biliary tract cancer.

    12 monthsAuthorization period for initial and reauthorization approvals
    <19 yearsAge threshold for automatic processing without coverage review
    KRAS G12CRequired mutation for covered adult oncology indications
    5Covered disease categories with criteria in this document
    1, 2A, or 2BNCCN evidence and consensus categories accepted

    Krazati Coverage Criteria

    Members less than 19 years of age

    Covered when the member is less than 19 years of age.

    Pediatric eligibility: Patient is less than 19 years of age<19 years

    Authorization is issued for 12 months.

    NSCLC initial authorization

    Covered when all of the following are met.

    NSCLC initial therapy

    • Diagnosis of non-small cell lung cancer (NSCLC)
    • Mutation: Presence of KRAS G12C mutationKRAS G12C positive
    • Disease status

      • Recurrent: Disease is recurrent
      • Advanced: Disease is advanced
      • Metastatic: Disease is metastatic
    • Prior therapy: Patient has received at least one prior systemic therapy≥1 prior systemic therapy

    NSCLC reauthorization

    Covered when the following continuation criterion is met.

    Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    CNS cancer initial authorization

    Covered when all of the following are met.

    CNS cancer initial therapy

    • Brain metastases: Diagnosis of limited or extensive brain metastases associated with non-small cell lung cancer (NSCLC)Limited or extensive
    • Mutation: Presence of KRAS G12C mutationKRAS G12C positive

    CNS cancer reauthorization

    Covered when the following continuation criterion is met.

    Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    Small bowel adenocarcinoma initial authorization

    Covered when all of the following are met.

    Small bowel adenocarcinoma initial therapy

    • Diagnosis of small bowel adenocarcinoma
    • Mutation: Presence of KRAS G12C mutationKRAS G12C positive
    • Disease status

      • Disease is recurrent
      • Disease is advanced

    Small bowel adenocarcinoma reauthorization

    Covered when the following continuation criterion is met.

    Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    Appendiceal neoplasm initial authorization

    Covered when all of the following are met.

    Appendiceal neoplasm initial therapy

    • Diagnosis of appendiceal neoplasm
    • Mutation: Presence of KRAS G12C mutationKRAS G12C positive
    • Disease status

      • Disease is recurrent
      • Disease is advanced

    Appendiceal neoplasm reauthorization

    Covered when the following continuation criterion is met.

    Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    Colorectal cancer initial authorization

    Covered when all of the following are met.

    Colorectal cancer initial therapy

    • Diagnosis of colorectal cancer
    • Mutation: Presence of KRAS G12C mutationKRAS G12C positive
    • Disease status

      • Disease is recurrent
      • Disease is advanced

    Colorectal cancer reauthorization

    Covered when the following continuation criterion is met.

    Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    Colorectal cancer initial therapy

    Covered for initial authorization when ALL of the following are met.

    Colorectal cancer initial authorization

    • Disease status

      • Disease is recurrent.
      • Disease is advanced.
      • Disease is metastatic.

    Ampullary adenocarcinoma initial therapy

    Covered for initial authorization when ALL of the following are met.

    Ampullary adenocarcinoma initial authorization

    • Disease status

      • Disease is recurrent.
      • Disease is advanced.
      • Disease is metastatic.

    Pancreatic adenocarcinoma initial therapy

    Covered for initial authorization when ALL of the following are met.

    Pancreatic adenocarcinoma initial authorization

    • Disease status

      • Disease is recurrent.
      • Disease is advanced.
      • Disease is metastatic.

    Biliary tract cancer initial therapy

    Covered for initial authorization when ALL of the following are met.

    Biliary tract cancer initial authorization

    • Diagnosis

      • Diagnosis of gallbladder cancer.
      • Diagnosis of intrahepatic cholangiocarcinoma.
      • Diagnosis of extrahepatic cholangiocarcinoma.
    • Disease status

      • Disease is unresectable.

    Colorectal cancer reauthorization

    Covered for reauthorization when the following criterion is met.

    Continued response or stable disease: Patient does not show evidence of progressive disease while on Krazati therapy.No evidence of progressive disease

    Authorization will be issued for 12 months.

    Ampullary adenocarcinoma reauthorization

    Covered for reauthorization when the following criterion is met.

    Continued response or stable disease: Patient does not show evidence of progressive disease while on Krazati therapy.No evidence of progressive disease

    Authorization will be issued for 12 months.

    Pancreatic adenocarcinoma reauthorization

    Covered for reauthorization when the following criterion is met.

    Continued response or stable disease: Patient does not show evidence of progressive disease while on Krazati therapy.No evidence of progressive disease

    Authorization will be issued for 12 months.

    Biliary tract cancer reauthorization

    Covered for reauthorization when the following criterion is met.

    Continued response or stable disease: Patient does not show evidence of progressive disease while on Krazati therapy.No evidence of progressive disease

    Authorization will be issued for 12 months.

    NCCN recommended regimens

    Coverage is available when the following criterion is met.

    NCCN recommended regimen: The drug is recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.NCCN Category of Evidence and Consensus 1, 2A, or 2B

    Authorization will be issued for 12 months. State mandates, federal regulatory requirements, member-specific benefit plan coverage, and other policies or utilization management programs may also affect coverage.

    Authorization and Documentation Requirements

    Note

    Age-Based Coverage Review

    Members younger than 19 years are processed automatically without a coverage review. Members aged 19 years and older must meet the applicable coverage criteria before Krazati is authorized.

    • Members younger than 19 years: automatic processing; authorization is issued for 12 months.
    • Members aged 19 years and older: coverage review required.
    • State-mandated benefit coverage or compendium requirements supersede these criteria where applicable.
    Prior Authorization

    NSCLC Initial Authorization

    Prior authorization is required for initial Krazati treatment for NSCLC. Approve for 12 months when the required diagnosis, KRAS G12C mutation, disease status, and prior systemic therapy criteria are documented.

    • Diagnosis of NSCLC.
    • Presence of a KRAS G12C mutation.
    • Disease is recurrent, advanced, or metastatic.

    Krazati Clinical Background

    Krazati (adagrasib) is an inhibitor of the RAS GTPase family. Its labeled uses include treatment as a single agent for adults with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) after at least one prior systemic therapy, and in combination with cetuximab for adults with KRAS G12C-mutated, locally advanced or metastatic colorectal cancer (CRC) after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

    Initial Authorization Criteria

    Pediatric initial authorization

    Members less than 19 years of age are approved based on age alone.

    Pediatric eligibility: Patient is less than 19 years of age<19 years

    Authorization is issued for 12 months.

    NSCLC

    For NSCLC, all criteria must be met.

    NSCLC: Diagnosis of NSCLC; KRAS G12C mutation; recurrent, advanced, or metastatic disease; and at least one prior systemic therapyAt least 1 prior systemic therapy

    Authorization is issued for 12 months.

    Reauthorization and Continuation Therapy

    Reauthorization

    Reauthorization is available when the patient does not show evidence of progressive disease while on Krazati therapy.

    Continuation therapy: Patient does not show evidence of progressive disease while on Krazati therapyNo progressive disease

    Authorization is issued for 12 months.

    Krazati continuation therapy

    Reauthorization is available when the patient does not show evidence of progressive disease while on Krazati therapy.

    Continuation requirement: No evidence of progressive disease while on Krazati therapy.No progressive disease

    Each reauthorization is issued for 12 months.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyKrazati (adagrasib) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for members 19 years and older using the applicable disease-specific or NCCN-recommended regimen criteria.
    SourceLink
    On This Page
    Krazati Coverage CriteriaAuthorization and Documentation RequirementsKrazati Clinical BackgroundInitial Authorization CriteriaReauthorization and Continuation Therapy
    Disease is metastatic
  1. Prior therapy: Patient has received at least one prior systemic therapy≥1 prior systemic therapy
  2. Disease is metastatic
    Disease is metastatic
  3. Prior therapy: Patient has received at least one prior systemic therapy≥1 prior systemic therapy
  4. Disease is resected gross residual (R2).
    R2
  5. Disease is metastatic.
  6. Patient has received at least one prior systemic therapy.
  7. Authorization duration: 12 months.
  8. Prior Authorization

    CNS Metastases Authorization

    Prior authorization is required for initial Krazati treatment for limited or extensive brain metastases associated with NSCLC. Both the diagnosis and KRAS G12C mutation must be documented.

    • Diagnosis of limited or extensive brain metastases associated with NSCLC.
    • Presence of a KRAS G12C mutation.
    • Authorization duration: 12 months.
    Prior Authorization

    Small Bowel Adenocarcinoma Authorization

    Prior authorization is required for initial Krazati treatment of small bowel adenocarcinoma. Approve for 12 months when all required clinical criteria are documented.

    • Diagnosis of small bowel adenocarcinoma.
    • Presence of a KRAS G12C mutation.
    • Disease is recurrent, advanced, or metastatic.
    • Patient has received at least one prior systemic therapy.
    • Authorization duration: 12 months.
    Prior Authorization

    Appendiceal Neoplasm Authorization

    Prior authorization is required for initial Krazati treatment of appendiceal neoplasm. Approve for 12 months when the diagnosis, KRAS G12C mutation, and qualifying disease status are documented.

    • Diagnosis of appendiceal neoplasm.
    • Presence of a KRAS G12C mutation.
    • Disease is recurrent, advanced, or metastatic.
    • Authorization duration: 12 months.
    Prior Authorization

    Colorectal Cancer Authorization

    Prior authorization is required for initial Krazati treatment of colorectal cancer. Approve for 12 months when all required clinical criteria are documented.

    • Diagnosis of colorectal cancer.
    • Presence of a KRAS G12C mutation.
    • Disease is recurrent, advanced, or metastatic.
    • Patient has received at least one prior systemic therapy.
    • Authorization duration: 12 months.
    Prior Authorization

    Prior Authorization Required

    Obtain prior authorization before initiating Krazati and submit documentation for the applicable initial-authorization indication. Reauthorization is also required and is issued for 12 months when continuation criteria are met.

    • Initial authorization applies to the covered indications addressed in the policy, including NSCLC, CNS metastases associated with NSCLC, small bowel adenocarcinoma, appendiceal neoplasm, colorectal cancer, ampullary adenocarcinoma, pancreatic adenocarcinoma, and specified biliary tract cancers.
    • Initial authorization duration: 12 months.
    • Reauthorization duration: 12 months.
    • The indication must be recognized by the NCCN Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B, where applicable.
    Documentation Required

    Clinical Eligibility Information

    Submit clinical documentation supporting the applicable diagnosis, KRAS G12C mutation, disease status, and prior treatment history. The required elements vary by indication.

    • Diagnosis: NSCLC; limited or extensive brain metastases associated with NSCLC; small bowel adenocarcinoma; appendiceal neoplasm; colorectal cancer; ampullary adenocarcinoma; pancreatic adenocarcinoma; or gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma.
    • Document presence of a KRAS G12C mutation.
    • Document qualifying disease status: recurrent, advanced, or metastatic; for the specified biliary cancers, unresectable, resected gross residual (R2), or metastatic.
    • Document at least one prior systemic therapy when required by the indication.
    Documentation Required

    Continuation Documentation

    For reauthorization, submit documentation showing that the patient does not have evidence of progressive disease while receiving Krazati therapy.

    • Continuation documentation is required for each applicable indication.
    • Authorization duration upon approval: 12 months.
    Denial Risk

    NSCLC Criteria Not Met

    NSCLC initial authorization criteria are not met when the required diagnosis, KRAS G12C mutation, qualifying disease status, or prior systemic therapy is absent or undocumented.

    • No diagnosis of NSCLC.
    • No documented KRAS G12C mutation.
    • Disease is not recurrent, advanced, or metastatic.
    • Patient has not received at least one prior systemic therapy.
    Denial Risk

    CNS Criteria Not Met

    Initial authorization for CNS metastases associated with NSCLC is not met when the required brain-metastases diagnosis or KRAS G12C mutation is absent or undocumented.

    • No diagnosis of limited or extensive brain metastases associated with NSCLC.
    • No documented KRAS G12C mutation.
    Denial Risk

    Small Bowel Adenocarcinoma Criteria Not Met

    Small bowel adenocarcinoma initial authorization criteria are not met when any required clinical element is absent or undocumented.

    • No diagnosis of small bowel adenocarcinoma.
    • No documented KRAS G12C mutation.
    • Disease is not recurrent, advanced, or metastatic.
    • Patient has not received at least one prior systemic therapy.
    Denial Risk

    Appendiceal Criteria Not Met

    Appendiceal neoplasm initial authorization criteria are not met when the required diagnosis, KRAS G12C mutation, or qualifying disease status is absent or undocumented.

    • No diagnosis of appendiceal neoplasm.
    • No documented KRAS G12C mutation.
    • Disease is not recurrent, advanced, or metastatic.
    Denial Risk

    Colorectal Cancer Criteria Not Met

    Colorectal cancer initial authorization criteria are not met when any required clinical element is absent or undocumented.

    • No diagnosis of colorectal cancer.
    • No documented KRAS G12C mutation.
    • Disease is not recurrent, advanced, or metastatic.
    • Patient has not received at least one prior systemic therapy.
    Denial Risk

    Progressive Disease at Reauthorization

    Reauthorization may be denied when the patient has evidence of progressive disease while receiving Krazati therapy.

    • Document that the patient does not show evidence of progressive disease during treatment.
    • Progressive disease during therapy does not meet the continuation criterion.
    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied for the additional covered indications when the applicable diagnosis, KRAS G12C mutation, disease status, or prior systemic therapy requirement is not met.

    • Ampullary adenocarcinoma: diagnosis, KRAS G12C mutation, recurrent/advanced/metastatic disease, and at least one prior systemic therapy are required.
    • Pancreatic adenocarcinoma: diagnosis, KRAS G12C mutation, recurrent/advanced/metastatic disease, and at least one prior systemic therapy are required.
    • Gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma: qualifying diagnosis, KRAS G12C mutation, unresectable/resected gross residual (R2)/metastatic disease, and at least one prior systemic therapy are required.
    Denial Risk

    Progressive Disease During Therapy

    Reauthorization may be denied when progressive disease is documented during Krazati therapy for the applicable indications.

    • Ampullary adenocarcinoma: no evidence of progressive disease is required.
    • Pancreatic adenocarcinoma: no evidence of progressive disease is required.
    • Gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma: no evidence of progressive disease is required.
    • Progressive disease during therapy does not meet the reauthorization criterion.

    Central nervous system cancers

    For CNS metastases, all criteria must be met.

    CNS metastases: Limited or extensive brain metastases associated with NSCLC and KRAS G12C mutationKRAS G12C positive

    Authorization is issued for 12 months.

    Small bowel adenocarcinoma

    For small bowel adenocarcinoma, all criteria must be met.

    Small bowel adenocarcinoma: Diagnosis of small bowel adenocarcinoma; KRAS G12C mutation; recurrent, advanced, or metastatic disease; and at least one prior systemic therapyAt least 1 prior systemic therapy

    Authorization is issued for 12 months.

    Appendiceal neoplasms and cancers

    For appendiceal neoplasms, all criteria must be met.

    Appendiceal neoplasm: Diagnosis of appendiceal neoplasm; KRAS G12C mutation; and recurrent, advanced, or metastatic diseaseKRAS G12C positive

    Authorization is issued for 12 months.

    Colorectal cancer

    For colorectal cancer, all criteria must be met.

    Colorectal cancer: Diagnosis of colorectal cancer; KRAS G12C mutation; recurrent, advanced, or metastatic disease; and at least one prior systemic therapyAt least 1 prior systemic therapy

    Authorization is issued for 12 months.

    Krazati initial authorization

    Initial authorization requires the applicable cancer diagnosis, KRAS G12C mutation, qualifying disease status, and at least one prior systemic therapy.

    Initial therapy requirements: Meet the diagnosis-specific criteria for colorectal cancer, ampullary adenocarcinoma, pancreatic adenocarcinoma, or biliary tract cancer; demonstrate a KRAS G12C mutation; meet the applicable disease-status requirement; and have received at least one prior systemic therapy.At least one prior systemic therapy

    Initial authorization is issued for 12 months.

    NCCN-based initial authorization

    Initial authorization may also be based on NCCN recognition of the cancer indication.

    NCCN pathway: The drug is recognized for treatment of the cancer indication by the NCCN Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.Category 1, 2A, or 2B

    Authorization is issued for 12 months.